Evidence map›Paper›PMID 38300559›Full record

ArticleInvestigative ophthalmology & visual science2024

Potential Structural Biomarkers in 3D Images Validated by the First Functional Biomarker for Early Age-Related Macular Degeneration - ALSTAR2 Baseline.

Sohaib Fasih-Ahmad, Ziyuan Wang, Zubin Mishra, Charles Vatanatham, Mark E Clark, Thomas A Swain, Christine A Curcio, Cynthia Owsley, SriniVas R Sadda, Zhihong Jewel Hu

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Impaired Rod-Mediated Vision is the Functional Hallmark of Ageing and Early and Intermediate Age-Related Macular Degeneration.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Complement Factor H and itsbioRxiv : the preprint server for biology · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sohaib Fasih-AhmadDoheny Eye Institute, Pasadena, California, United States.
Ziyuan WangDoheny Eye Institute, Pasadena, California, United States.
Zubin MishraDoheny Eye Institute, Pasadena, California, United States.
Charles VatanathamDoheny Eye Institute, Pasadena, California, United States.
Mark E ClarkOphthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Thomas A SwainOphthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Christine A CurcioOphthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Cynthia OwsleyOphthalmology and Visual Sciences, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States.
SriniVas R SaddaDoheny Eye Institute, Pasadena, California, United States.
Zhihong Jewel HuDoheny Eye Institute, Pasadena, California, United States.
Doheny Eye Institute · USUniversity of Alabama at Birmingham · US

Funding

Functionally Validated Structural Endpoints for Early AMDR01EY029595 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CURCIO, CHRISTINE A, OWSLEY, CYNTHIA · 2019 to 2023
$4.1M
Discovery and Validation of AMD Biomarkers for Progression Using Deep LearningR21EY030619 · NEI · DOHENY EYE INSTITUTE · PI HU, ZHIHONG, SADDA, SRINIVAS R · 2019 to 2020
$432k
NEI NIH HHS R01 EY029595NEI NIH HHS R21 EY030619
6 · The paper itself

Abstract

Purpose: Lack of valid end points impedes developing therapeutic strategies for early age-related macular degeneration (AMD). Delayed rod-mediated dark adaptation (RMDA) is the first functional biomarker for incident early AMD. The relationship between RMDA and the status of outer retinal bands on optical coherence tomography (OCT) have not been well defined. This study aims to characterize these relationships in early and intermediate AMD. Methods: Baseline data from 476 participants was assessed including eyes with early AMD (n = 138), intermediate AMD (n = 101), and normal aging (n = 237). Participants underwent volume OCT imaging of the macula and rod intercept time (RIT) was measured. The ellipsoid zone (EZ) and interdigitation zone (IZ) on all OCT B-scans of the volumes were segmented. The area of detectable EZ and IZ, and mean thickness of IZ within the Early Treatment Diabetic Retinopathy Study (ETDRS) grid were computed and associations with RIT were assessed by Spearman's correlation coefficient and age adjusted. Results: Delayed RMDA (longer RIT) was most strongly associated with less preserved IZ area (r = -0.591; P < 0.001), followed by decreased IZ thickness (r = -0.434; P < 0.001), and EZ area (r = -0.334; P < 0.001). This correlation between RIT and IZ integrity was not apparent when considering normal eyes alone within 1.5 mm of the fovea. Conclusions: RMDA is correlated with the status of outer retinal bands in early and intermediate AMD eyes, particularly, the status of the IZ. This correlation is consistent with a previous analysis of only foveal B-scans and is biologically plausible given that retinoid availability, involving transfer at the interface attributed to the IZ, is rate-limiting for RMDA.

Indexed as

Macula LuteaMacular DegenerationBiomarkersFovea CentralisHumansNonoxynolRetinaBiomarkersNonoxynol

Identifiers

PMID38300559
PMCPMC10846345
OpenAlexW4391430774

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.